A Randomized Study of Paclitaxel – Carboplatin followed by maintenance Niraparib versus Paclitaxel – Carboplatin – Bevacizumab followed by maintenance Niraparib + Bevacizumab in Patients With Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer Following a Front-Line Complete Cytoreduction Surgery
Niraparib vs Niraparib in combination with Bevacizumab in patients with carboplatinum-taxane based chemotherapy in advanced ovarian cancer (A multicentre randomised phase III trial)
A Phase 3, Open-label, Multicenter, Randomized Study of Trastuzumab Deruxtecan with Bevacizumab Versus Bevacizumab Monotherapy as First-line Maintenance Therapy in HER2‑Expressing, Homologous-Recombination Deficiency Negative Ovarian Cancer DESTINY- OVARIAN 01 (DO-01)
Phase 3, Randomized, Open-label, Multicenter Study of MK-2870 Maintenance With or Without Bevacizumab Versus Standard of Care in Participants With Newly-Diagnosed Advanced HRD-Negative Ovarian Cancer Following First-line Platinum-based Chemotherapy
A Phase III randomized, open label study of NiraParib maintenance after Carboplatin and Paclitaxel in optimaLly debUlked advanced HRDpositive high-grade ovarian cancer patientS
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rucaparib in combination with Nivolumab versus Placebo as Switch Maintenance Following Response to Front-Line Platinum-Based Chemotherapy in Patients with High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination with Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER
Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer (EOC)
A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety,Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors
A Phase 2/3, Multicenter, Randomized Study of Raludotatug Deruxtecan (R-DXd), a CDH6-directed Antibody-drug Conjugate, in Subjects with Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancers
Phase 3 radomized controlled trial evaluating Avutometinib and Defactinib vs Standard of Care Treatment (Investigators choice) in patients with recurrent LGSOC
A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of MK-2870 Maintenance Treatment With or Without Bevacizumab Versus Standard of Care After Second-line Platinum-based Doublet Chemotherapy in Participants With Platinum-sensitive Recurrent Ovarian Cancer.
A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigator’s Choice (IC) in Patients with Platinum Resistant Ovarian Cancer
A Phase 2/3 Open-label Study Evaluating the Efficacy and Safety of Luveltamab Tazevibulin (STRO-002) versus Investigator’s Choice of Chemotherapy in Women with Relapsed Platinum-resistant Epithelial Ovarian Cancer (including Fallopian Tube or Primary Peritoneal Cancers) Expressing Folate Receptor alpha (FOLR1)
A Phase 2 study evaluating the efficacy and safety of TORL-1-23 in Women with advanced platinum resistant epithelial ovarian cancer (including primary peritoneal and fallopian tube cancers) expressing Claudin 6 (CLdn6)
A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Investigator’s choice in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer
A phase III randomized, double-blinded trial of platinum-based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal or peritoneal cancer and platinum treatment-free interval (TFIp) >6 months
Phase III, multi-center, randomized (1:1), open label, active-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with olaparib as compared to single agent cytotoxic chemotherapy (wPac or PLD), in participants with no germline BRCA mutation detected, platinum-resistant or refractory, HGSOC
A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator’s Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression
A phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination with Pembrolizumab Versus Investigator’s Choice Chemotherapy in Patients with Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 200kHz) concomitant with weekly paclitaxel for the treatment of patients with recurrent ovarian cancer not suitable for platinum treatment (ROC-NP)
A Phase 3 Randomized, Active-Controlled, Open-Label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician’s Choice as Second-Line or Third-Line Treatment for Participants with Recurrent or Metastatic Cervical Cancer
A Randomized Phase III Trial of Platinum Chemotherapy plus Paclitaxel with Bevacizumab and Atezolizumab versus Platinum Chemotherapy plus Paclitaxel and Bevacizumab in Metastatic (stage IVB), Persistent, or Recurrent Carcinoma of the Cervix
A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin versus Investigator’s Choice Chemotherapy in Second or Third Line Metastatic or Recurrent Cervical Cancer”
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-centre, Global Study of Volrustomig in Women with High Risk Locally Advanced Cervical Cancer Who Have Not Progressed Following Platinum-based, Concurrent Chemoradiation Therapy (eVOLVE-Cervical)
A randomized, open label, phase II trial of Anti-PD1, dostarlimab (TSR-042), as maintenance therapy for patients with high-risk locally advanced cervical cancer after chemo-radiation
A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer”
Randomized phase III trial in MMR deficient endometrial cancer patients comparing chemotherapy alone versus Dostarlimab in first line advanced/metastatic setting)
A PHASE 3, Randomized, placebo-controlled, Double-Blind, multicenter Trial of selinexor in Maintenance therapy After systemic therapy for Patients with P53 Wild-TYPE, Advanced or Recurrent Endometrial carcinoma
A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician’s Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-Based Chemotherapy and Immunotherapy
A Phase III, randomized, multi-site, open-label trial of BNT323/DB-1303 versus investigator’s choice of chemotherapy in previously treated patients with HER2-expressing recurrent or metastatic endometrial cancer.
“A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Participants With Recurrent or Advanced Endometrial Cancer Who Have Received Prior Platinum-Based Chemotherapy and Anti-PD-(L)1 Immunotherapy”
Phase III double-blind randomized placebo-controlled trial of atezolizumab in combination with paclitaxel and carboplatin in women with advanced/recurrent endometrial cancer
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma
A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab vs. Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma in the First-line Setting
A phase 3, randomized, double blind multicenter study of Dostarlimab (TSR-042) plus Carboplatin-Paclitaxel versus placebo plus Carboplatin-Paclitaxel in patients with recurrent or primary advance endometrial cancer
A Phase 3, Randomized, Double‐Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With or Without Radiotherapy for the Treatment of Newly Diagnosed High‐Risk Endometrial Cancer After Surgery With Curative Intent “
An international, prospective, randomized, multicenter, single blind trial to compare sentinel lymph node (SLN) biopsy versus SLN biopsy + pelvic lymphadenectomy in term of DFS and HR-QoL
Phase III Trial of Olaparib vs. Placebo in Patients with Advanced FIGO Stage IIIB – IV High Grade Serous or Endometrioid Ovarian, Fallopian Tube, or Peritoneal Cancer treated with standard First-Line Treatment, Combining Platinum-Taxane Chemotherapy and Bevacizumab Concurrent with Chemotherapy and in Maintenance.
Phase III study of Trabectedin plus Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin plus PLD in patients with ovarian cancer progressing within 6-12 months of last platinum.
Phase II study Carbo + DLP or paclitaxel with or without farletuzumabplatinum resistant relapses with low levels of CA 125.
Cerrado
Cáncer de Ovario
ENGOT-ov26/GEICO 54-O/PRIMA
PI: A. González
A Phase 3 Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy.
Estudio retrospectivo sobre tratamiento del cáncer de ovario.
Cerrado
Cáncer de Ovario
GEICO 44-R/RETRO-ROC
PI: I. Romero
Estudio post-autorización observacional restrospectivo y multicéntrico de la combinación con trabectedina y doxorubicinaliposomalpegilada (DLP) en cáncer de ovario recidivante.
CÓDIGO DE ENSAYO CLÍNICO: GEICO 1302 - ENGOT OV 11 - Array 162-311
PI: I. Romero
The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer): A Multinational, Randomized, Open-label Phase 3 Study of MEK162 vs. Physician’s Choice Chemotherapy in Patients with Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary, Fallopian Tube or Primary Peritoneum
Cerrado
Cáncer de Ovario
CÓDIGO DE ENSAYO CLÍNICO: GEICO 1303-ENGOT OV 16- NOVA (ENGOT)
PI: JM. Del Campo
A Phase 3 Randomized Double-Blind Trial of Maintenance with Niraparib Versus Placebo in Patients with Platinum Sensitive Ovarian Cancer
Cerrado
Cáncer de Ovario
ENGOT-OV-2b/TRINOVA 3/GEICO-1201
PI: JM. Del Campo
TRINOVA – A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study of AMG 386 With Paclitaxel and Carboplatin as First-line Treatment of Subjects With FIGO Stage III-IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers.
Cerrado
Cáncer de Ovario
MM-121/GEICO 1202
PI: A. González, A. Redondo, JM. Rubio, A. Poveda
Phase II Randomized Open Label Study of MM-121 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Platinum Resistant/ Refractory Advanced Ovarian Cancers.
Cerrado
Cáncer de Ovario
NCIC-OV 21/GEICO-0902
PI: I. Romero, J. Ponce
Estudio de Fase II-III de quimioterapia intraperitoneal (IP) más intravenosa (IV) frente a carboplatino más Paclitaxel IV en pacientes con carcinoma epitelial de ovario sometidas a cirugía citoreductora óptima posterior a quimioterapia intravenosa neoadyuvante.
Cerrado
Cáncer de Ovario
GEICO 1001-CATUMAXOMAB
PI: A. Oaknin
Ensayo Fase II para evaluar la eficacia y seguridad de catumaxomab como tratamiento de consolidación de pacientes con un carcinoma epitelial de ovario, de trompa de Falopio, o un carcinoma primario peritoneal en segunda o tercera remisión completa clínica.
Cerrado
Cáncer de Ovario
AGO-OVAR 12/GEICO 1003
PI: JM. Del Campo
Estudio de fase III, multicéntrico, aleatorizado y doble ciego para evaluar la eficacia y seguridad de BIBF 1120 en combinación con carboplatino y paclitaxel comparado con placebo en combinación con carboplatino y paclitaxel en pacientes con cáncer de ovario avanzado.
Cerrado
Cáncer de Ovario
GEICO 1002
PI: A. Oaknin
Ensayo clínico fase II no controlado, multicéntrico y prospectivo para determinar el beneficio clínico y toxicidad de Pazopanib, inhibidor multidiana de receptores con actividad tirosin-quinasa (VEGFR -1, -2 , -3, PDGFR-α y β y C-Kit), en pacientes con cáncer de ovario avanzado platino resistentes.
Cerrado
Cáncer de Ovario
ICON-6/GEICO 1101
PI: A. González
Ensayo clínico multicéntrico del Gynaecologic Cancer Intergroup, controlado doble ciego de Cediranib (AZD 2171), en combinación con quimioterapia basada en platino y como agente único en terapia de mantenimiento, en mujeres con cáncer de ovario que han recaído más de 6 meses tras la finalización de un tratamiento de primera línea basado en platino.
Cerrado
Cáncer de Ovario
AURELIA/GEICO 0904
PI: A. Poveda
AURELIA: Ensayo clínico de fase III multicéntrico, abierto, aleatorizado, con dos grupos de tratamiento, de bevacizumab en combinación con quimioterapia frente a quimioterapia sola en pacientes con cáncer epitelial de ovario, carcinoma de trompas de Falopio o peritoneal primario resistente a platino.
Cerrado
Cáncer de Ovario
GEICO 0901/AGO-OVAR 16
PI: JM del Campo
Estudio de fase III para evaluar la eficacia y la seguridad de pazopanib en monoterapia frente a placebo entre mujeres con cáncer epitelial de ovario, de trompa de Falopio o peritoneal primario que no hayan progresado después de la quimioterapia de primera línea.
Cerrado
Cáncer de Ovario
GEICO 0905-OCTAVIA
PI: A. González
A single-arm Phase II clinical study of the combination of carboplatin and weekly periclitar plus bevacizumab as first-line treatment in patients with epithelial ovarian cancer.
Cerrado
Cáncer de Ovario
GEICO 0802/HECTOR-PHASE III-2006
PI: A. González, A. Santaballa
Topotecán más carboplatino frente al tratamiento estándar (paclitaxel más carboplatino o gemcitabina más carboplatino) en el tratamiento de pacientes con carcinoma peritoneal, carcinoma de trompas o carcinoma epitelial de ovario plantino-sensibles recidivantes.
Cerrado
Cáncer de Ovario
GEICO 0804-R
PI: B. Ojeda
Base de datos de Bevacizumab en recaídas de Cáncer de Ovario.
Cerrado
Cáncer de Ovario
GEICO 0801-T
PI: A. Poveda
Estudio retrospectivo de biomarcadores en Cáncer Epitelial de Ovario.
Cerrado
Cáncer de Ovario
GEICO 0803-R
PI: A. Oaknin
Feasibility and toxicity of a modified outpatient regimen of intravenous/ intraperitoneal chemotherapy (IV/IP) in optimally debulked stage III ovarian cancer patients: A GEICO Study.
Cerrado
Cáncer de Ovario
GEICO 0701/ICON-7
PI: A. Cervantes
Estudio aleatorizado del “Gynaecologic Cancer InterGroup”, de dos grupos, multicéntrico para añadir bevacizumab a la quimioterapia estándar (carboplatino y paclitaxel) en pacientes que sufren cáncer epitelial de ovario.
Cerrado
Cáncer de Ovario
GEICO 0702-T/TOPO IIA
PI: A. González
Determinación de la expresión de TOPO IIA en muestras de carcinoma de ovario de pacientes tratadas con doxorubicina liposomal pegilada.
Cerrado
Cáncer de Ovario
GEICO 0703/MIMOSA
PI: A. Casado
Ensayo clínico multicéntrico aleatorizado, doble ciego, controlado con placebo, para evaluar el tratamiento de mantenimiento con abagovomab en pacientes afectas de carcinoma epitelial ovárico tras respuesta completa a la quimioterapia de la 1ª línea.
Cerrado
Cáncer de Ovario
GEICO 0104
PI: A. González
Estudio fase II randomizado del doblete carboplatino-gemcitabina seguido de carboplatino paclitaxel versus carboplatino-paclitaxel en pacientes con recidiva platinosensible de carcinoma de ovario, carcinomatosis peritoneal primaria o carcinoma de trompa.
Cerrado
Cáncer de Ovario
GEICO 0101
PI: MA. Izquierdo, A. Cervantes
Ensayo clínico de fase III para evaluar el tratamiento con la combinación cisplatino más topotecán seguido de paclitaxel más carboplatino frente a paclitaxel más carboplatino como tratamiento de primera línea en mujeres con un diagnóstico reciente de cáncer epitelial de ovario avanzado.
Cerrado
Cáncer de Ovario
GEICO 0103
PI: B. Ojeda
Estudio fase II, con Gemcitabina en infusión prolongada en pacientes con cáncer epitelial de ovario avanzado resistentes a platino
Cerrado
Cáncer de Ovario
GEICO CO22
PI: A. Casado
Validación por GEICO de CAELYX en pacientes con cáncer epitelial de ovario.
Cerrado
Cáncer de Ovario
GEICO 0199
PI: A. González
Ensayo clínico fase II randomizado (con valoración de calidad de vida) de carboplatino frente a la combinación de taxol y carboplatino en pacientes con recaída de cáncer de ovario platino-sensible.
Cerrado
Cáncer de Ovario
GEICO 0299/EORTC 55981/NSGO
PI: MA. Izquierdo, JM del Campo
Ensayo Clínico aleatorizado de Paclitaxel / Epirubicina / Carboplatino en combinación (TEC) vs Paclitaxel / Carboplatino (TC) en el tratamiento de mujeres con cáncer de ovario avanzado.
Cerrado
Cáncer de Ovario
ENGOT OV68/GEICO 112-O/ARTISTRY 7
PI: A. Redondo
A phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination with Pembrolizumab Versus Investigator’s Choice Chemotherapy in Patients with Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
A Phase 3, Randomized, Double-Blind, Adaptive, Placebo/Paclitaxel-Controlled Study of AVB-S6-500 in Combination with Paclitaxel in Patients with Platinum-Resistant Recurrent Ovarian Cancer
Multicentric Single arm Phase II clinical trial, to evaluate safety and efficacy of the combination of olaparib and PLD for platinum resistant ovarian primary peritoneal carcinoma, and fallopian tube cancer patients
A Phase IIIb, Randomised, Double-blind, Placebo-controlled, multi-centre Study of Olaparib Maintenance Re-treatment in Patients with Epithelial Ovarian Cancer Previously treated with a PARPi and Responding to Repeat Platinum Chemotherapy (OReO)
Cerrado
Cáncer de Ovario
ENGOT-ov21/GEICO 39-O/SOLO-2
PI: A. Poveda
Phase III Randomised, Double Blind, Placebo Controlled Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients With a Complete or Partial Response Following Platinum Based Chemotherapy
Retrospective multicenter study of elderly patients with platinum-sensitive relapsed ovarian cancer treated with trabectedin and pegylated liposomal doxorubicin (pld) in a real-world setting: a geico study
Cerrado
Cáncer de Ovario
ENGOT-ov25/GEICO 48-O/PAOLA
PI: A. González / R. Marquez
Phase III Trial of Olaparib vs. Placebo in Patients with Advanced FIGO Stage IIIB – IV High Grade Serous or Endometrioid Ovarian, Fallopian Tube, or Peritoneal Cancer treated with standard First-Line Treatment, Combining Platinum-Taxane Chemotherapy and Bevacizumab Concurrent with Chemotherapy and in Maintenance
Cerrado
Cáncer de Ovario
ENGOT-ov39/GEICO 63-O/IMAGYN 050
PI: Y. García
A Phase III study of Atezolizumab versus Placebo administered in combination with Paclitaxel, Carboplatin, and Bevacizumab for patients with new diagnosed stage III/stage IV Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
A phase III study of atezolizumab versus placebo in patients with late relapse of epithelial ovarian, fallopian tube, or peritoneal cancer treated by platinum-based chemotherapy and bevacizumab.
A Randomized, Multicenter, Open-label, Phase III Study of Lurbinectedin in Combination with Paclitaxel vs. Platinum-based Chemotherapy or Weekly Paclitaxel as Treatment in Patients with Relapsed Platinum-sensitive Ovarian Cancer
Cancelado
Cáncer de Ovario
ENGOT-ov71/GEICO 121-O/UP-NEXT
PI: Mª. Jesús Rubio
Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Upifitamab Rilsodotin (XMT-1536) as Post-Platinum Maintenance Therapy for Participants with Recurrent, Platinum-Sensitive, High-grade Serous Ovarian Cancer
Cancelado
Cáncer de Ovario
ENGOT OV75/ GEICO 128-O/INNOVATE 5
PI: A. Taus
A Pivotal, Randomized Controlled, Open-Label Study of Tumor Treating Fields (TT Fields) in Patients with Recurrent Ovarian Cancer in Whom Platinum Is an Option
Cancelado
Cáncer de Ovario
ENGOT gyn2/GEICO 97-O/BOUQUET
PI: A. Redondo
A phase II, open-label, multicenter, platform study evaluating the efficacy and safety of biomarker-driven therapies in patients with persistent or recurrent rare epithelial ovarian tumors.
Cerrado
Cáncer de Cérvix
ENGOT-Cx6/GEICO 73-C
PI: A. González
A Phase 2 Trial of TisotumabVedotin (HuMax®-TF- ADC) alone or in Combination in First Line Recurrent or Stage IVB Cervical Cancer.
Cerrado
Cáncer de Cérvix
ENGOT-CX1/GEICO 43-O
PI: MJ Rubio
Estudio de fase II, de tratamiento cada 3 semanas con carboplatino (AUC 5) + 175 mg/m2de paclitaxel, con o sin nintedanib concomitante y de mantenimiento, en el carcinoma de cuello uterino avanzado o recidivante.
Fase II carbo-paclitaxel-bevacizumab en primera línea del carcinoma de cérvix persistente, recurrente o diseminado.
Cerrado
Cáncer de Cérvix
GOG-0240 / GEICO-0903
PI: A. Oaknin
Ensayo en Fase III aleatorizado de Cisplatino más Paclitaxel con y sin Bevacizumab frente al doblete sin platino, Topotecan más Paclitaxel, con y sin Bevacizumab, en carcinoma de cérvix en estadio IVB, recurrente o persistente.
Cerrado
Cáncer de Cérvix
GEICO 2005/01
PI: MJ Rubio
Estudio exploratorio fase II para evaluar la eficacia y seguridad de topotecan semanal en el tratamiento de cáncer de cérvix persistente o recidivante tras fracaso de tratamiento de primera línea con derivados del platino.
Cerrado
Cáncer de Cérvix
ENGOT-cx9/GEICO 72-C/EMPOWER Cx-1 // REGENERON
PI: A. Oaknin
Randomized, open-label, phase III clinical trial of REGN2810 compared to investigator's choice chemotherapy treatment for recurrent or metastatic platinum-resistant cervical carcinoma
Estudio de fase II, aleatorizado y doble ciego que compara el tratamiento cada 3 semanas con carboplatino (AUC 5) + 175 mg/m2 de paclitaxel, con o sin nintedanib concomitante y de mantenimiento, en el carcinoma de cuello uterino avanzado o recidivante
A Phase III trial of postoperative chemotherapy or no further treatment for patients with node negative stage I/II intermediate or high-risk endometrial cancer.
A phase II trial of Palbociclib in combination with Letrozole versus Letrozole Monotherapy for patients with Estrogen Receptor Positive advanced or recurrent Endometrial cancer.
Yondelis en leiomiosarcoma uterino: estudio retrospectivo + biomarcadores.
Cerrado
Cáncer de Endometrio
GEICO P02868/GEIS 7
PI: Andrés Poveda
Ensayo Fase IV-II de Temozolamida en esquema de administración oral continua en el tratamiento de los Sarcomas Ginecológicos.
Cerrado
Cáncer de Endometrio
ENGOT-en5/GEICO 67-E/SIENDO
PI: J.A. Pérez Fidalgo
A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY AFTER SYSTEMIC THERAPY FOR PATIENTS WITH P53 WILD-TYPE, ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA
A PHASE II MULTICENTER, OPEN-LABEL, SINGLE ARM TRIAL OF AVELUMAB IN COMBINATION WITH PEGYLATED LIPOSOMAL DOXORUBICIN IN RECURRENT/METASTATIC ENDOMETRIAL CANCER
A Multiregional, Randomized, Double-Blinded, Placebo-Controlled Phase 3 Study of Lerociclibwith Letrozole, versus Placebo with Letrozole, in pts with Advanced/Metastatic or Recurrent, Grade 1 or Grade 2 Endometrioid Endometrial Carcinoma”
Cancelado
Cáncer de Endometrio
ENGOT-en21/GEICO 126-E/KRT-232-118
PI: Josefa Ferreiro
A Two-part, Randomized Phase 2/3 Study of Navtemadlin in Subjects with TP53WT Advanced or Recurrent Endometrial Cancer Who Responded after Chemotherapy”
Gestión de Cookies
Utilizamos cookies propias y de terceros para el correcto funcionamiento, visualización y uso del sitio web por parte del usuario y para mejorar nuestros servicios recogiendo datos estadísticos sobre la navegación de los usuarios en el sitio web. Puede obtener más información sobre las cookies que utilizamos e incluso rechazarlas consultando nuestra Política de cookies. Pulsando el botón 'Aceptar' presta su consentimiento para el uso de las cookies mencionadas.
Funcional
Siempre activo
El almacenamiento o acceso técnico es estrictamente necesario para el propósito legítimo de permitir el uso de un servicio específico explícitamente solicitado por el abonado o usuario, o con el único propósito de llevar a cabo la transmisión de una comunicación a través de una red de comunicaciones electrónicas.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Estadísticas
El almacenamiento o acceso técnico que es utilizado exclusivamente con fines estadísticos.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
El almacenamiento o acceso técnico es necesario para crear perfiles de usuario para enviar publicidad, o para rastrear al usuario en una web o en varias web con fines de marketing similares.
